(Q37870181)

24 August 2017

1 reference

title

Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients (English)

1 reference

24 August 2017

1 reference

dasatinib monohydrate

1 reference

1 reference

chronic myeloid leukemia

1 reference

1 reference

2

Giuliana Alimena

1 reference

24 August 2017

1

Massimo Breccia

1 reference

24 August 2017

publication date

1 June 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

25

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

147-157

1 reference

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Regulation of the c-Abl and Bcr-Abl tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Chronic myelogenous leukemia: biology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

HIV-Associated Primary Bone Marrow Hodgkin's Lymphoma: A Distinct Entity?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Dasatinib and chronic myeloid leukemia: two-year follow-up in eight clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591840-000000000-00000

10.2165/11591840-000000000-00000

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

24 August 2017

1043906776

0 references

1 reference